Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed pancreatic ductal adenocarcinoma~* Administration of 2nd-line nab-paclitaxel plus gemcitabine~* Progression on 1st-line FOLFIRINOX~Exclusion Criteria:~* Pathologic diagnosis other than pancreatic ductal adenocarcinoma~* Administration of nab-paclitaxel plus gemcitabine as 3rd or greater lines of therapy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nab-P + GEM (Type: None): Nab-paclitaxel plus gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).